Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Mecasermin, sold under the brand name Increlex, also known as recombinant human insulin-like growth factor-1 (rhIGF-1), is a recombinant form of human insulin-like growth factor 1 (IGF-I) which is used in the long-term treatment of growth failure and short stature in children with severe primary IGF-I deficiency, for instance due to growth hormone deficiency or Laron syndrome (growth hormone insensitivity).
Read the full article on WikipediaSevere growth failure with primary insulin-like growth factor-1 deficiency Clinical criteria: Treatment Phase: Initial treatment The condition must be caused by severe primary insulin-like growth factor-1 deficiency (IGFD), with IGFD deficiency for the purpose of PBS subsidy defined as a basal IGF-1 level (measured any time prior to initiating treatment with this drug) below the 2.5th percentile adjusted for each of: (i) age, (ii) gender, AND The condition must have resulted in the patient experiencing short stature, with short stature for the purpose of PBS subsidy defined as the patient's height (measured any time prior to initiating treatment with this drug) being at least 3 standard deviations below the norm, adjusted for each of: (i) age, (ii) gender, AND Patient must have a growth velocity below the 25th percentile for bone age and sex measured over a 12 month interval (or a 6 month interval for an older child), AND The condition must not be caused by growth hormone deficiency, AND Patient must have a bone age of less than 13.5 years (females); OR Patient must have a bone age of less than 15.5 years (males), AND The condition must not be caused by secondary causes of IGFD - prior to initiating treatment with this drug, the treating physician has at least excluded each of the following: (i) malnutrition, (ii) hypopituitarism, (iii) hypothyroidism, (iv) medication side effects, AND The treatment must not be in a patient with known epiphyseal closure/growth plate fusion (i.e. the patient is known to have ceased growing). Treatment criteria: Must be treated by a paediatric endocrinologist; the authority application must be completed by this physician type; OR Must be treated by a paediatrician who has consulted the above mentioned specialist type; the authority application must be completed by this paediatrician. Population criteria: Patient must be aged from 2 years up until their 18th birthday. An older child is defined as a male with a chronological age of at least 12 years or a bone age of at least 10 years, or a female with a chronological age of at least 10 years or a bone age of at least 8 years. The initial treatment authority application must be made via the Online PBS Authorities System (real time assessment) or in writing via HPOS form upload or mail and must include the following: (1) Insulin-like growth factor-1 deficiency: State each of: (a) the patient's most recent basal IGF-1 level measured (ng/mL), (b) the measurement date (dd/mm/yy), (c) the name of the pathology result provider; (2) Short stature: State the patient's height (cm); (3) Normal growth hormone levels: State the patient's most recent growth hormone level measurement (mcg/L) - this figure must be greater than 6.6 mcg/L; (4) Bone age: (where the patient has a chronological age of at least 2.5 years): State each of: (a) the patient's bone age in numerical figures at the time when it was most recently determined, (b) the date (dd/mm/yy) of this determination that is within 12 months of this authority application; (5) The patient's weight (kg); (6) The prescribed dose (mg/kg) (between 0.04 to 0.12); (7) The number of vials rounded to the nearest whole number, to provide sufficient drug quantity for 30 days of treatment per dispensing - see the relevant 'NOTE' attached to this listing for guidance. Height, growth velocity and weight measurements must not be more than three months old at the time of application. If the application is submitted through HPOS form upload or mail, it must include: (i) details of the proposed prescription; and (ii) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).
“5.8 hours”
Working under the parallel aged-care framework? Aged-care equivalent →